• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors.

作者信息

Cucchi David G J, Van Alphen Carolien, Zweegman Sonja, Van Kuijk Bo, Kwidama Zinia J, Al Hinai Adil, Henneman Alexander A, Knol Jaco C, Piersma Sander R, Pham Thang V, Jimenez Connie R, Cloos Jacqueline, Janssen Jeroen J W M

机构信息

Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, The Netherlands.

OncoProteomics Laboratory, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, The Netherlands.

出版信息

Hemasphere. 2021 Jun 12;5(7):e606. doi: 10.1097/HS9.0000000000000606. eCollection 2021 Jul.

DOI:10.1097/HS9.0000000000000606
PMID:34136754
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8202661/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bfd/8202661/e11da2194bd3/hs9-5-e606-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bfd/8202661/a9b8b81d1af8/hs9-5-e606-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bfd/8202661/e11da2194bd3/hs9-5-e606-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bfd/8202661/a9b8b81d1af8/hs9-5-e606-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bfd/8202661/e11da2194bd3/hs9-5-e606-g002.jpg

相似文献

1
Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors.原发性急性髓系白血病样本的磷酸化蛋白质组学特征及其与对FLT3抑制剂反应的相关性
Hemasphere. 2021 Jun 12;5(7):e606. doi: 10.1097/HS9.0000000000000606. eCollection 2021 Jul.
2
Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.Pim激酶调节FLT3-ITD急性髓系白血病对FLT3酪氨酸激酶抑制剂的耐药性。
Sci Adv. 2015 Sep 18;1(8):e1500221. doi: 10.1126/sciadv.1500221. eCollection 2015 Sep.
3
The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplications is associated with reduced apoptosis in response to FLT3 inhibitors.伴有FLT3内部串联重复的急性髓系白血病（AML）细胞中P-糖蛋白的表达与对FLT3抑制剂反应时凋亡减少相关。
Br J Haematol. 2004 Oct;127(1):26-33. doi: 10.1111/j.1365-2141.2004.05145.x.
4
Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.抑制Flt3激活突变并不能阻止某些急性髓系白血病（AML）细胞中ERK/Akt/STAT信号通路的组成性激活：这可能是小分子抑制剂单药治疗效果有限的一个原因。
Hematol Oncol. 2007 Mar;25(1):30-7. doi: 10.1002/hon.805.
5
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition.携带FLT3/ITD突变的儿童急性髓系白血病原代样本可被FLT3抑制优先杀伤。
Blood. 2004 Sep 15;104(6):1841-9. doi: 10.1182/blood-2004-03-1034. Epub 2004 May 27.
6
miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.微小RNA-155通过抑制干扰素反应促进FLT3-ITD诱导的骨髓增殖性疾病。
Blood. 2017 Jun 8;129(23):3074-3086. doi: 10.1182/blood-2016-09-740209. Epub 2017 Apr 21.
7
BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.BH3模拟物ABT-737可消除原发性急性髓系白血病母细胞中由BCL2非FLT3依赖性表达介导的对FLT3抑制剂治疗的耐药性。
Leukemia. 2007 Aug;21(8):1763-72. doi: 10.1038/sj.leu.2404776. Epub 2007 Jun 7.
8
Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.ITD 分类可预测接受 FLT3 抑制剂治疗的 AML 患者的结局。
Clin Cancer Res. 2019 Jan 15;25(2):573-583. doi: 10.1158/1078-0432.CCR-18-0655. Epub 2018 Sep 4.
9
LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.LAM-003，一种用于治疗酪氨酸激酶抑制剂耐药的 FLT3-ITD 阳性 AML 的新药。
Blood Adv. 2019 Nov 26;3(22):3661-3673. doi: 10.1182/bloodadvances.2019001068.
10
Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.双重 FLT3 抑制剂：近十年对抗急性髓系白血病耐药性的策略
Eur J Med Chem. 2019 Sep 15;178:468-483. doi: 10.1016/j.ejmech.2019.06.002. Epub 2019 Jun 5.

引用本文的文献

1
Integrating multi-omics approaches in acute myeloid leukemia (AML): Advancements and clinical implications.整合多组学方法用于急性髓系白血病（AML）：进展与临床意义。
Clin Exp Med. 2025 Aug 31;25(1):311. doi: 10.1007/s10238-025-01858-x.
2
Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia.组学在急性髓系白血病诊断、预后及治疗中的应用。
Biomark Res. 2024 Jun 10;12(1):60. doi: 10.1186/s40364-024-00600-1.
3
Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues.

本文引用的文献

1
Two decades of targeted therapies in acute myeloid leukemia.急性髓细胞白血病的靶向治疗二十年。
Leukemia. 2021 Mar;35(3):651-660. doi: 10.1038/s41375-021-01164-x. Epub 2021 Feb 15.
2
The influence of delay in mononuclear cell isolation on acute myeloid leukemia phosphorylation profiles.单核细胞分离延迟对急性髓系白血病磷酸化谱的影响。
J Proteomics. 2021 Apr 30;238:104134. doi: 10.1016/j.jprot.2021.104134. Epub 2021 Feb 6.
3
FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research-a systematic review and meta-analysis.
胰腺导管腺癌中的激酶活性及其预后和治疗途径。
Mol Oncol. 2024 Aug;18(8):2020-2041. doi: 10.1002/1878-0261.13625. Epub 2024 Apr 22.
4
The 2023 Report on the Proteome from the HUPO Human Proteome Project.2023 年人类蛋白质组组织蛋白质组报告。
J Proteome Res. 2024 Feb 2;23(2):532-549. doi: 10.1021/acs.jproteome.3c00591. Epub 2024 Jan 17.
5
Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics.使用基于质谱的（磷酸化）蛋白质组学鉴定晚期肾细胞癌患者中可能从舒尼替尼治疗中获益的生物标志物
Clin Proteomics. 2023 Nov 8;20(1):49. doi: 10.1186/s12014-023-09437-6.
6
Principles of phosphoproteomics and applications in cancer research.磷酸化蛋白质组学原理及其在癌症研究中的应用。
Biochem J. 2023 Mar 31;480(6):403-420. doi: 10.1042/BCJ20220220.
7
Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine.急性髓系白血病的蛋白质组学特征用于精准医学。
Mol Cell Proteomics. 2023 Apr;22(4):100517. doi: 10.1016/j.mcpro.2023.100517. Epub 2023 Feb 18.
8
Proteomic characterization of post-translational modifications in drug discovery.药物发现中翻译后修饰的蛋白质组学特征。
Acta Pharmacol Sin. 2022 Dec;43(12):3112-3129. doi: 10.1038/s41401-022-01017-y. Epub 2022 Nov 13.
9
The 2022 Report on the Human Proteome from the HUPO Human Proteome Project.《人类蛋白质组组织 2022 年人类蛋白质组报告》。
J Proteome Res. 2023 Apr 7;22(4):1024-1042. doi: 10.1021/acs.jproteome.2c00498. Epub 2022 Nov 1.
10
Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.蛋白质组学和磷酸化蛋白质组学测量增强了预测急性髓系白血病离体药物反应的能力。
Clin Proteomics. 2022 Jul 27;19(1):30. doi: 10.1186/s12014-022-09367-9.
FLT3 抑制剂在急性髓细胞白血病中的应用：临床疗效、不良事件和未来研究的评估——系统评价和荟萃分析。
Syst Rev. 2020 Dec 7;9(1):285. doi: 10.1186/s13643-020-01540-1.
4
Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome.原代急性髓系白血病样本的体外培养和药物测试：当前技术以及对实验设计和结果的影响。
Drug Resist Updat. 2020 Dec;53:100730. doi: 10.1016/j.drup.2020.100730. Epub 2020 Oct 10.
5
Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.FLT3突变型和FLT3野生型急性髓系白血病患者中米哚妥林药物敏感性的基因组标志物
Oncotarget. 2020 Jul 21;11(29):2807-2818. doi: 10.18632/oncotarget.27656.
6
Potential targeting of FLT3 acute myeloid leukemia.FLT3 急性髓系白血病的潜在靶点。
Haematologica. 2021 Mar 1;106(3):671-681. doi: 10.3324/haematol.2019.240754.
7
Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines.基于磷酸酪氨酸的磷酸化蛋白质组学在 AML 细胞系中的靶标鉴定和药物反应预测。
Mol Cell Proteomics. 2020 May;19(5):884-899. doi: 10.1074/mcp.RA119.001504. Epub 2020 Feb 26.
8
MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia.MEK 抑制增强了急性髓系白血病对酪氨酸激酶抑制剂的反应。
Sci Rep. 2019 Dec 9;9(1):18630. doi: 10.1038/s41598-019-54901-9.
9
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases.INKA，一种综合数据分析管道，用于磷酸化蛋白质组学推断活性激酶。
Mol Syst Biol. 2019 Apr 12;15(4):e8250. doi: 10.15252/msb.20188250.
10
RNA-based -ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML.基于 RNA 的 ITD 等位基因比与儿科 AML 的结局和体外对 FLT3 抑制剂的反应相关。
Blood. 2018 May 31;131(22):2485-2489. doi: 10.1182/blood-2017-12-819508. Epub 2018 Apr 18.